Home >  ENT >  ENT News >  Meclizine May Ease...

Meclizine May Ease Dizziness but Raises Chances of Injurious Falls, Study Shows

Written By :  Medha Baranwal
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2025-08-22 16:15 GMT   |   Update On 2025-08-22 16:16 GMT
Advertisement

USA: A large U.S. cohort study found meclizine, a common vestibular suppressant for dizziness, is linked to a significantly higher risk of injurious falls in both younger and older adults. The findings, from Dr. Meredith E. Adams and colleagues at the University of Minnesota, were published in JAMA Otolaryngology–Head & Neck Surgery.

Meclizine, an antihistamine with anticholinergic effects, provides short-term relief from
vertigo and dizziness. However, routine use is questioned due to sedative properties and potential to impair balance and cognition, which increase fall risk. The new analysis highlights safety concerns when prescribing meclizine, especially for patients vulnerable to falls.
Researchers reviewed data from over 805,000 adults diagnosed with dizziness (2006–2015). Of these, 62,000 (8%) filled a meclizine prescription within 30 days. Outcomes were compared between those who did and did not receive meclizine.
Advertisement
The study led to the following findings:
  • 9% of meclizine users experienced an injurious fall within 60 days of prescription, compared with 4% of patients who did not receive the drug.
  • After adjusting for sociodemographic and clinical factors, meclizine use was linked to a nearly threefold higher risk of injurious falls among adults aged 18 to 64 years (HR, 2.94).
  • Patients aged 65 years and older had a 2.5-fold higher risk of injurious falls associated with meclizine use (HR, 2.54).
  • The elevated risk was observed across both younger and older adults, indicating that the harms are not limited to older populations.
  • While older adults are already prone to balance issues and falls, younger adults with dizziness were also significantly affected.
“Although meclizine may offer immediate symptom relief, our findings indicate that its use is inconsistent with evidence-based guidelines for common vestibular disorders and may expose patients to unnecessary harm,” the authors noted.
The study highlights the importance of re-evaluating prescribing practices for dizziness. Falls are a major cause of morbidity, hospitalization, and loss of independence in both older and middle-aged adults. The inappropriate use of vestibular suppressants such as meclizine may therefore contribute to preventable adverse outcomes.
The researchers suggest that prospective clinical trials and mechanistic studies are needed to better understand the relationship between vestibular suppressant medications and fall risk. They also emphasized the need for future clinical guidelines that discourage routine meclizine prescriptions for dizziness and instead promote safer, evidence-based management strategies.
"While meclizine has been widely used for decades to treat dizziness, this large-scale study highlights a significant safety trade-off. Clinicians are encouraged to weigh the short-term symptomatic benefits against the long-term risks of falls, and to consider alternative approaches that align with best practice recommendations,' the authors concluded.
Reference:
Adams ME, Karaca-Mandic P, Marmor S. Meclizine Use and Subsequent Falls Among Patients With Dizziness. JAMA Otolaryngol Head Neck Surg. Published online July 24, 2025. doi:10.1001/jamaoto.2025.2052


Tags:    
Article Source : JAMA Otolaryngology–Head & Neck Surgery

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal
Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Metformin Improves Lung Function and Symptom Control in Asthma Patients with Metabolic Syndrome: Study

Levodropropizine A Valuable Peripheral Anti-tussive for Dry Cough in Primary Care Settings: Latest Indian Clinicians' Review

Increase in blood SIRI levels elevates the risk of COPD: Study

Indian Pulmonologists Release Evidence-Based Expert Review for Optimizing Nebulization in the Management of Obstructive Airway Disorders

Hyperbaric Oxygen Therapy Enhances Hearing Recovery in Sudden Sensorineural Hearing Loss Patients: Study

Hospitalisation in COPD Patients Linked to Sharp Rise in Cardiovascular Events and Mortality: Study

FDA Approves Brensocatib as First Treatment for Non-Cystic Fibrosis Bronchiectasis